Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Christina Poh, Xueyan Chen, Jenna M. Voutsinas, Edus H. Warren, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Sindhu Cherian, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2024-205892

Published: 2024

Journal Articles

Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL)

Ntasha Roy, Zhengwei (Jenny) Mao, Chang Xu, David T. Teachey, Zhiguo (Bruce) Chen, Meenakshi Devidas, Xueyan Chen, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Brent L. Wood

Blood (2023) 142 (Supplement 1): 2976.

https://doi.org/10.1182/blood-2023-190624

Published: 2023

Journal Articles

Treatment Outcomes for Adults with Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study

Jennifer J. Huang, Jacob S. Appelbaum, Kathryn Russell, Carole Shaw, Ashley M. Eckel, Xueyan Chen, Rutu D. Vyas, Paul C. Hendrie, Anna B. Halpern, Raya Mawad, Ryan D Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival, Cristina Maria Ghiuzeli

Blood (2023) 142 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2023-188461

Published: 2023

Journal Articles

Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation

Melinda Ann Biernacki, Olivia Waltner, Sami B Kanaan, Rula Green Gladden, Shruti Bhise, Todd M. Cooper, Monica Thakar, Soheil Meshinchi, Marie Bleakley, Xueyan Chen, Scott N Furlan

Blood (2022) 140 (Supplement 1): 10215–10216.

https://doi.org/10.1182/blood-2022-171164

Published: 2022

Journal Articles

Myeloid/Lymphoid Neoplasm with Eosinophilia and a Novel RUFY1-Pdgfrb Rearrangement

Karly Williams Silva, Carrie L. Cummings, Nahid Rashid, Olga Sala-Torra, Xueyan Chen, Yajuan J. Liu, Vivian G. Oehler

Blood (2021) 138 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2021-151703

Published: 2021

Journal Articles

Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma

Chang Xu, Ally Studer, Xueyan Chen, MD, Eric Hoyle, David Wu, MD PhD, Zhengwei Mao, Brent L Wood, MD PhD

Blood (2019) 134 (Supplement_1): 1475.

https://doi.org/10.1182/blood-2019-131360

Published: 2019

Journal Articles

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

Xueyan Chen, MD, Megan Othus, PhD, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2692.

https://doi.org/10.1182/blood-2019-124977

Published: 2019

Journal Articles

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Blood (2019) 133 (17): 1876–1887.

https://doi.org/10.1182/blood-2018-11-887067

Published: 2019

Includes: Supplemental data

Journal Articles

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Blood (2019) 133 (15): 1652–1663.

https://doi.org/10.1182/blood-2018-11-883710

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2018-99-116745

Published: 2018

Journal Articles

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2018-99-115126

Published: 2018

Journal Articles

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Blood (2018) 132 (Supplement 1): 281.

https://doi.org/10.1182/blood-2018-99-110561

Published: 2018

Journal Articles

Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

Joshua A. Hill, Daniel Li, Kevin A. Hay, Margaret L. Green, Sindhu Cherian, Xueyan Chen, Stanley R. Riddell, David G. Maloney, Michael Boeckh, Cameron J. Turtle

Blood (2018) 131 (1): 121–130.

https://doi.org/10.1182/blood-2017-07-793760

Published: 2018

Includes: Supplemental data

Journal Articles

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Kevin A. Hay, Laïla-Aïcha Hanafi, Daniel Li, Juliane Gust, W. Conrad Liles, Mark M. Wurfel, José A. López, Junmei Chen, Dominic Chung, Susanna Harju-Baker, Sindhu Cherian, Xueyan Chen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2017) 130 (21): 2295–2306.

https://doi.org/10.1182/blood-2017-06-793141

Published: 2017

Includes: Supplemental data

Journal Articles

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Cameron J Turtle, MBBS, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Laila-Aicha Hanafi, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 184.

https://doi.org/10.1182/blood.V126.23.184.184

Published: 2015

Journal Articles

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 3773.

https://doi.org/10.1182/blood.V126.23.3773.3773

Published: 2015

Journal Articles

Immunophenotypic Features of Myeloid Stem Cell Neoplasms Associated with Monosomy 7

Xueyan Chen, MD PhD, Sindhu Cherian, MD

Blood (2014) 124 (21): 1051.

https://doi.org/10.1182/blood.V124.21.1051.1051

Published: 2014

Journal Articles

The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia

Xueyan Chen, MD, PhD, Hu Xie, Carl Bohm, Brent L. Wood, MD, PhD, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Roland B. Walter, MD, PhD, Ravinder K Sandhu, MD, Janis L Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 1418.

https://doi.org/10.1182/blood.V120.21.1418.1418

Published: 2012

NARROW

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL)

Treatment Outcomes for Adults with Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study

Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation

Myeloid/Lymphoid Neoplasm with Eosinophilia and a Novel RUFY1-Pdgfrb Rearrangement

Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Immunophenotypic Features of Myeloid Stem Cell Neoplasms Associated with Monosomy 7

The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only